Want to see HK:3320 full AI Analyst Report?
3320 Stock Chart & Stats
HK$4.61
HK$0.05(0.94%)
At close: 4:00 PM EST
HK$4.61
HK$0.05(0.94%)
Day’s Range― - ―
52-Week RangeHK$4.22 - HK$6.53
Previous CloseN/A
Volume6.08M
Average Volume (3M)13.76M
Market Cap
HK$26.64B
Enterprise ValueHK$102.85B
Total Cash (Recent Filing)HK$31.05B
Total Debt (Recent Filing)HK$104.87B
Price to Earnings (P/E)6.0
Beta0.77
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.95%
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,282,510,300
10 Day Avg. Volume13,454,154
30 Day Avg. Volume13,759,791
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)0.49
Price to Sales (P/S)0.09
P/FCF Ratio1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.82Price Target Upside47.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Integrated Business ModelOperating across distribution, retail pharmacies and manufacturing gives stable, multi-channel revenue streams and vertical synergies. This reduces single-channel risk, supports cross-selling, and preserves durable market access as hospitals, clinics and consumers rely on its nationwide logistics and retail network.
Solid Cash GenerationConsistent operating and free cash flow materially above reported earnings improves earnings quality and funds reinvestment, dividends or debt servicing. Strong cash conversion provides resilience during cyclical pressures and supports strategic spending without immediate external financing.
Steady Revenue Growth; Improving Gross MarginsRecurring mid-single-digit revenue growth with improving gross margins suggests durable demand and operational enhancements. This trend supports long-term scale benefits, helps stabilize operating margins, and provides room to absorb cost pressures while maintaining investment in distribution and retail footprints.
Bears Say
Rising Financial LeverageMaterial increase in leverage raises refinancing and interest-rate vulnerability. Higher debt reduces financial flexibility for acquisitions or capital spending, heightens default risk under stress, and makes the company more sensitive to credit market tightening over the medium term.
Very Thin Net MarginsPersistently low net margins limit earnings leverage from revenue growth and reduce retained earnings for investment. With thin bottom-line profitability, the company has less buffer against margin shocks, constraining its ability to fund growth or accelerate deleveraging without external capital.
OCF Covers Small Portion Of DebtAlthough cash generation is solid, operating cash flow only services a small fraction of total debt annually, limiting rapid deleveraging. This structural gap constrains balance-sheet repair and raises refinancing risk if credit conditions tighten, pressuring long-term financial stability.
China Resources Pharmaceutical Group Ltd. News
3320 FAQ
What was China Resources Pharmaceutical Group Ltd.’s price range in the past 12 months?
China Resources Pharmaceutical Group Ltd. lowest stock price was HK$4.22 and its highest was HK$6.53 in the past 12 months.
What is China Resources Pharmaceutical Group Ltd.’s market cap?
China Resources Pharmaceutical Group Ltd.’s market cap is HK$26.64B.
When is China Resources Pharmaceutical Group Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were China Resources Pharmaceutical Group Ltd.’s earnings last quarter?
Currently, no data Available
Is China Resources Pharmaceutical Group Ltd. overvalued?
According to Wall Street analysts China Resources Pharmaceutical Group Ltd.’s price is currently Undervalued.
Does China Resources Pharmaceutical Group Ltd. pay dividends?
China Resources Pharmaceutical Group Ltd. pays a Quarterly dividend of HK$0.139 which represents an annual dividend yield of 2.95%. See more information on China Resources Pharmaceutical Group Ltd. dividends here
What is China Resources Pharmaceutical Group Ltd.’s EPS estimate?
China Resources Pharmaceutical Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Resources Pharmaceutical Group Ltd. have?
China Resources Pharmaceutical Group Ltd. has 6,282,510,300 shares outstanding.
What happened to China Resources Pharmaceutical Group Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of China Resources Pharmaceutical Group Ltd.?
Currently, no hedge funds are holding shares in HK:3320
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China Resources Pharmaceutical Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$6.82 (47.94% Upside)
HK$6.82 (47.94% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
7.98%
Trailing 12-Months
Asset Growth
2.12%
Trailing 12-Months
Company Description
China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
3320 Stock 12 Month Forecast
Average Price Target
HK$6.82
▲(47.94% Upside)
Technical Analysis
The United Laboratories International Holdings
―
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
Options Prices
Currently, No data available
---